Navigation Links
Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Year
Date:2/6/2012

ST. LOUIS, Feb. 6, 2012 /PRNewswire/ -- Young Innovations, Inc. (NASDAQ – YDNT) today announced record earnings per share for the fourth quarter and record sales and EPS for the year.

Sales for the fourth quarter of 2011 were $26.7 million, an increase of 3.2% from the $25.9 million reported for the fourth quarter of 2010. Income from operations for the fourth quarter increased 5.1% to $6.1 million from $5.8 million in the prior year quarter. Net income for the fourth quarter increased 14.8% to $4.3 million from $3.8 million in the fourth quarter of 2010. Diluted earnings per share for the fourth quarter of 2011 were $0.54, an increase of 14.9% over the $0.47 reported in the prior year quarter. In the quarter, diluted earnings per share were affected by equity compensation expense of $0.04, compared to $0.03 in the prior year quarter.  Diluted earnings per share for the fourth quarter were positively affected by other income of $0.04 from the Company's investment in a private equity fund. Diluted shares outstanding were 7.9 million for the quarter, down 1.2% from 8.0 million in the prior year quarter.

Sales for the year ended December 31, 2011 were $106.2 million, up 3.3% from $102.8 million in the prior year. Income from operations increased 5.8% to $24.4 million in 2011 from $23.0 million in the prior year. Net income for fiscal year 2011 was $16.5 million, up 10.1% from $14.9 million in the prior year. Diluted earnings per share were $2.05 for the twelve months ended December 31, 2011, an increase of 10.2% from $1.86 in 2010. During the year, diluted earnings per share were affected by equity compensation expense of $0.15, compared to $0.14 in the prior year. Diluted earnings per share for 2011 were positively affected by other income of $0.08 from the Company's investment in a private equity fund. Diluted shares outstanding were 8.0 million for the year, unchanged from the prior year.

We are pleased that sales finished the year up 3% in a challenging economic environment. Sales growth reflected solid demand for our consumable product offering throughout the year.  In addition, we continued to experience increased demand for diagnostic products following strong growth in 2010.

During the quarter, we remained focused on executing our strategy for growth. We successfully launched a new line of disposable prophylaxis angles and our recent introduction of the Encompass digital panoramic system continued to gain traction in the market. In addition, we completed the consolidation of certain administrative functions and light manufacturing into our Algonquin facility.

As previously announced, in addition to the quarterly cash dividend of $0.04 per share, the Company issued a special cash dividend of $1.00 per share in the fourth quarter of 2011. Our strong balance sheet and cash flows enabled us to pay this dividend to our shareholders while still preserving significant capacity to invest in strategic growth opportunities as we ended the year with a modest net cash balance.

We believe that our organization continued to strengthen throughout the year. We successfully launched new products across our consumable and diagnostic product lines. We improved operating efficiency across the business through production automation and the consolidation of various administrative functions. We also remained focused on enhancing relationships with our distribution partners as well as the end users of our products.  Although we are mindful of the impact a weak economy has on the overall demand for dental services, we continue to believe that the execution of our strategy will position the Company for future growth and success.

A conference call has been scheduled for Tuesday, February 7, 2012 at 11:00 A.M. Central Time and can be accessed through InterCall at http://tinyurl.com/Quarter42011 or the Company's website, www.ydnt.com.

Young Innovations develops, manufactures and markets supplies and equipment used by dentists, dental hygienists, dental assistants and consumers. The Company's consumables product offering includes disposable and metal prophy angles, prophy cups and brushes, dental micro-applicators, moisture control products, infection control products, dental handpieces (drills) and related components, endodontic systems, orthodontic toothbrushes, flavored examination gloves, children's toothbrushes, and children's toothpastes. In addition, the Company offers a line of diagnostic products that includes panoramic X-ray machines and related supplies. The Company believes it is a leading U.S. manufacturer or distributor of prophy angles and cups, liquid surface disinfectants, dental micro-applicators and obturation units designed for warm, vertical condensation.

Investors are cautioned that this press release as well as other reports and oral statements by Company officials may contain certain forward-looking statements as defined in the Private Securities Litigation and Reform Act of 1995.  Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions and which include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," or similar expressions.  These statements are not guarantees of future performance and the Company makes no commitment to update or disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.  Because such statements involve risks and uncertainties, actual actions and strategies and the timing and expected results thereof may differ materially from those expressed or implied by such forward-looking statements.  These risks and uncertainties include, but are not limited to, those disclosed in the Company's Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission.Young Innovations, Inc.Consolidated Statements of Income(In thousands, except earnings per share data)(Unaudited)(In Thousands USD)Three Months EndedTwelve Months EndedDecember 31,December 31,20112010

Change20112010

ChangeNet Sales

$
26,681$
25,860

3.2%$  106,230$   102,842

3.3%Cost of Goods Sold

$
2,196$
,678

4.4%$
47,521$
45,681

4.0%Gross Profit

$
4,485$
4,182

2.1%$
58,709$
57,161

2.7%% of Net Sales

54.3%54.8%55.3%55.6%Selling, General and Administrative Expense

$
8,349$
8,342

0.1%$
34,349$
34,141

0.6%% of Net Sales

31.3%32.3%32.3%33.2%Income from Operations

6,1365,840

5.1%24,36023,020

5.8%% of Net Sales

23.0%22.6%22.9%22.4%Interest expense, net

5859236322Other income (expense), net

477211,046(107)Income Before Taxes

6,5555,802

13.0%25,17022,805

10.4%Provision for Income Taxes

2,2402,0428,7177,868Net Income

$
4,315$
3,760

14.8%$
,453$
4,937

10.1%% of Net Sales

16.2%14.5%15.5%14.5%Basic Earnings Per Share

$
.54$
.47

14.9%$
2.06$
.87

10.2%Basic Weighted Average Shares Outstanding

7,9317,9667,9937,969Earnings Per Share (Diluted)

$
.54$
.47

14.9%$
2.05$
.86

10.2%Diluted Weighted Average Shares Outstanding

7,9368,0368,0338,037YI ConsolidatedConsolidated Balance SheetDecember 31, 2011 and December 31, 2010(In Thousands USD)(Unaudited)December 31December 31Assets20112010Current assetsCash$
,031$
741Accounts receivable, net12,06611,721Inventories17,16117,260Other current assets4,7294,861Total current assets34,98734,583Property, plant and equipment, net32,27233,162Goodwill80,25480,289Intangible assets11,13011,579Other assets1,1432,012Total assets$
59,786$
,625Liabilities and EquityCurrent liabilitiesAccounts payable and accrued liabilities$
9,134$
,700Total current liabilities9,13410,700Long-term debt6506,100Long-term secured borrowing956Deferred income taxes19,53417,417Other noncurrent liabilities206248Total liabilities29,53334,521Stockholders' equityCommon stock102102Additional paid-in capital24,70824,190Retained earnings158,647151,458Common stock in treasury, at cost(52,924)(48,484)Accumulated other comprehensive income(280)(162)Total stockholders' equity130,253127,104Total liabilities and stockholders' equity$
59,786$
,625
'/>"/>

SOURCE Young Innovations, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Younger Adults Increasingly Treated for Heart Disease-related Conditions
2. New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions
3. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
4. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
5. St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors
6. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
7. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
8. Young Women Diagnosed with Early-Stage Breast Cancer More Likely to Die than Older Women
9. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
10. Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
11. Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... YORK , December 2, 2016 ... 5,251.11, down 1.36%; the Dow Jones Industrial Average edged 0.36% ... at 2,191.08, down 0.35%. Losses were broad based as six ... Stock-Callers.com has initiated research reports on the following Services equities: ... (NASDAQ: QGEN ), INC Research Holdings Inc. (NASDAQ: ...
(Date:12/2/2016)... , Dec. 1, 2016 Around the ... country, region and each habitable land present over earth. ... every individual once in a life time this is ... care available until now. Given the steady increase in ... together with the spiraling healthcare costs of treatment, there ...
(Date:12/2/2016)... The iShares Nasdaq Biotechnology Exchange-Traded Fund ... victory early in November. Less political risk has boosted ... predicting an uptick in M&A activities. Today, Stock-Callers.com takes ... they have fared at the last close: Celldex Therapeutics ... (NASDAQ: FOLD ), Navidea Biopharmaceuticals Inc. (NYSE ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... office, will speak at the American Conference Institute’s 21st Drug & Medical Device ... a Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical ...
(Date:12/2/2016)... ... 2016 , ... Advanced Inc., a leading provider of travel therapy and travel ... serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served ... and operational leadership experience to Advanced Inc. He began his career in finance at ...
(Date:12/2/2016)... PITTSBURGH, PA (PRWEB) , ... December 02, 2016 , ... ... or struggling through rehabilitation of an injury, patients must find the one that works ... for his pain, he created a machine that worked and decided to share it ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):